When Making Babies Goes High Tech: A Future Tense Event Recap
By Ariel Bogle,
Slate
| 11. 24. 2014
[Quotes CGS's Marcy Darnovsky]
Untitled Document
In vitro fertilization was originally intended to help a very specific young, married, and female demographic to conceive. But a lot has changed since Louise Brown, the first test tube baby, was born in 1978. The explosion of single mothers and same-sex parents using the procedure has attracted a lot of attention, but society also needs to grapple with the questions of control, regulation, and access that other emerging reproductive technologies could raise. From pre-implantation genetic screening to exo-wombs, these changes could even evolve our most basic notions of family and society.
A first step may be agreeing to talk about this possible future at all. The highly personal nature of reproductive science and technology makes it a difficult topic to discuss and legislate, according to speakers at a Future Tense event on the future of reproduction in Washington, D.C., last week. After all, we’re not talking about hip replacement surgery; this is our future children and grandchildren. As Dieter Egli, a senior research fellow at the New York Stem Cell Foundation, put it: “When we touch the...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...